Bob Wasserman has been following healthcare and biotech stocks for over 30 years, with a bias toward value investing. He has been quoted and appeared in a number of print and media outlets, and his education includes degrees from MIT and the University of Chicago. He currently lives in Florida.
Recent Articles By The Author
5 Ways Allergan Can Keep Up Momentum
Allergan's most-recent quarterly financial report for Q4/2016 showed solid results.
Skin in the Game: This Dermatology Market Stock Is a Good M&A Bet
Oculus Innovative Sciences represents a good buy for value investors or cash-rich companies such as Allergan.
How to Invest in Your Favorite MD
Iora Health just raised $75 million in funding and has 34 clinics in 11 states, including Boston and New York.
Rebound May Be in Store for Beaten-Down Shares of TherapeuticsMD
Although many biotechnology stocks have fallen this year due to disappointing clinical trial results, what is the deal with this stock that is down precipitously despite encouraging R&D news?
Momenta, Coherus BioSciences Are Both Good Options in the Biosimilar Space
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.